AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17009499 — intervention group
Group type: COMPARATOR
Intervention: Vision-only group
Number of subjects: 20
Study 14627847 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG dual-head coincidence gamma camera imaging (DHC)
Number of subjects: 42
Study 14627847 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose positron emission tomography (FDG PET)
Number of subjects: 42
Study 14627847 — intervention group
Group type: COMPARATOR
Intervention: Traditional staging
Number of subjects: 42
Study 14627847 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 42
Study 10878691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 30
Study 10878691 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 8937620 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg)
Number of subjects: 11
Study 8937620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1554660 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel (2 mg) instilled into the posterior fornix, with a further dose of 1 mg if contractions did not commence after 6 hours
Number of subjects: 230
Study 1554660 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (observation for up to 24 hours)
Number of subjects: 230
Study 3884767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (TTC) with freeze-dried bone allografts (FDBA)
Number of subjects: 16
Study 3884767 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (TTC) plus debridement only
Number of subjects: 16
Study 3884767 — intervention group
Group type: COMPARATOR
Intervention: Freeze-dried bone allografts (FDBA) alone
Number of subjects: 16
Study 3884767 — intervention group
Group type: COMPARATOR
Intervention: Debridement only
Number of subjects: 16
Study 29331848 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 9
Study 29331848 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 9
Study 27136412 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aerobic exercise
Number of subjects: 0
Study 27136412 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (general)
Number of subjects: 0
Study 23945965 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine controlled-release 40 mg b.i.d.
Number of subjects: 325
Study 23945965 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine controlled-release 40 mg q.d.
Number of subjects: 325
Study 21541696 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive behavioural therapy (CBT)
Number of subjects: 297
Study 21541696 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 297
Study 20487589 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 g/d WG cereal (WGM)
Number of subjects: 32
Study 20487589 — intervention group
Group type: COMPARATOR
Intervention: 48 g placebo cereal (non‐whole grain (NWG))
Number of subjects: 32
Study 17321105 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus internal distraction
Number of subjects: 50
Study 17321105 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus external distraction
Number of subjects: 50
Study 17321105 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus internal focus
Number of subjects: 50
Study 17321105 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus external focus
Number of subjects: 50
Study 17321105 — intervention group
Group type: COMPARATOR
Intervention: Exposure alone
Number of subjects: 50
Study 15692967 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide for treatment of SSc-associated interstitial lung disease
Number of subjects: 138
Study 15692967 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 138
Study 11845217 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) glasses during lumbar punctures
Number of subjects: 30
Study 11845217 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention during lumbar punctures (control group)
Number of subjects: 30
Study 10075141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 20 mg twice daily
Number of subjects: 188
Study 10075141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 7734095 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily for 1 week)
Number of subjects: 15
Study 7734095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2187912 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 79
Study 2187912 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 79
Study 2187912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 7009264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals (20, 40, and 60 g of complex carbohydrate)
Number of subjects: 24
Study 7009264 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (20, 40, and 60 g)
Number of subjects: 24
Study 7009264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 24
Study 30863463 — intervention group
Group type: EXPERIMENTAL
Intervention: Group seizure first aid training intervention
Number of subjects: 53
Study 28955715 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod 2 mg once daily (preceding treatment)
Number of subjects: 120
Study 28955715 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod 2 mg once daily (interrupted treatment)
Number of subjects: 120
Study 28955715 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod 2 mg once daily (concomitant treatment)
Number of subjects: 120
Study 28955715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28955715 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod 2 mg once daily (all groups)
Number of subjects: 120
Study 28955715 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod
Number of subjects: 120
Study 24957785 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 701
Study 24957785 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 701
Study 25590448 — intervention group
Group type: EXPERIMENTAL
Intervention: BIPAP Group (n=20)
Number of subjects: 60
Study 25590448 — intervention group
Group type: COMPARATOR
Intervention: EPAP Group (n=20)
Number of subjects: 60
Study 25590448 — intervention group
Group type: COMPARATOR
Intervention: IPPB Group (n=20)
Number of subjects: 60
Study 21069381 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 2.0 atm with inhalation of 100% oxygen for 60 min at 3, 24, and/or 48 hours after hepatectomy.
Number of subjects: 41
Study 21069381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBOT).
Number of subjects: 41
Study 19898575 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Thrombendarterectomy (CEA)
Number of subjects: 408
Study 19898575 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Stenting
Number of subjects: 408
Study 16897112 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanger bath therapy combined with amitriptyline (10 mg/day for 8 weeks)
Number of subjects: 50
Study 16897112 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (10 mg/day for 8 weeks) alone
Number of subjects: 50
Study 14962012 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 7 mg kg‐1
Number of subjects: 19
Study 14962012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11274240 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omega-3 fatty acids (EPA 3.76 g and DHA 2.94 g daily)
Number of subjects: 73
Study 11274240 — intervention group
Group type: COMPARATOR
Intervention: Low-dose omega-3 fatty acids (EPA 1.88 g and DHA 1.47 g daily)
Number of subjects: 73
Study 11274240 — intervention group
Group type: COMPARATOR
Intervention: Omacor-treated patients (63 patients)
Number of subjects: 73
Study 9674329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension, 15 mg/kg, single oral dose
Number of subjects: 26
Study 9674329 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 7517991 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 200,000/0.62 (HES)
Number of subjects: 22
Study 7517991 — intervention group
Group type: COMPARATOR
Intervention: Dextran 60,000
Number of subjects: 22
Study 2694158 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene plus canthaxanthin
Number of subjects: 11
Study 2694158 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene
Number of subjects: 11
Study 5171687 — intervention group
Group type: COMPARATOR
Intervention: Expressed human milk and proprietary breast-milk substitute (S26) with protein intake of not more than 4.5 g/kg/day
Number of subjects: 5
Study 5171687 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaporated milk formula with protein intake ranging from 6.15 to 12.3 g/kg/day
Number of subjects: 5
Study 5171687 — intervention group
Group type: COMPARATOR
Intervention: Normal feeds with normal protein intake
Number of subjects: 5
Study 31672458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (1600 mg three times daily)
Number of subjects: 50
Study 31672458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30998694 — intervention group
Group type: EXPERIMENTAL
Intervention: Age similarity manipulation (students)
Number of subjects: 582
Study 30998694 — intervention group
Group type: EXPERIMENTAL
Intervention: Age similarity manipulation (older adults)
Number of subjects: 582
Study 30998694 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived similarity
Number of subjects: 582
Study 28768531 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 14
Study 28768531 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 14
Study 28768531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Glycopyrronium + Indacaterol)
Number of subjects: 14
Study 28768531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 14
Study 28768531 — intervention group
Group type: COMPARATOR
Intervention: Non-asthmatic control
Number of subjects: 14
Study 25511789 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV), 500 mg/body every 12 hours until postoperative day 7
Number of subjects: 146
Study 25511789 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT), 15-18 mg/kg fosphenytoin followed by 125 mg PHT every 12 hours until postoperative day 7
Number of subjects: 146
Study 25511789 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) in subgroup analysis (no seizures before craniotomy)
Number of subjects: 146
Study 25511789 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT) in subgroup analysis (no seizures before craniotomy)
Number of subjects: 146
Study 25511789 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 146
Study 25511789 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 146
Study 23332040 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified cassava porridge with added oil (2 mg β-carotene, 15 ml peanut or rapeseed oil, 20 g total fat)
Number of subjects: 10
Study 23332040 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified cassava porridge without added oil (2 mg β-carotene, 6 g total fat)
Number of subjects: 10
Study 23332040 — intervention group
Group type: COMPARATOR
Intervention: Unfortified white cassava porridge with added oil (0.3 mg retinyl palmitate, 20 g total fat)
Number of subjects: 10
Study 20629074 — intervention group
Group type: EXPERIMENTAL
Intervention: Submandibular salivary gland transfer procedure
Number of subjects: 70
Study 20629074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 19221765 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 256
Study 19221765 — intervention group
Group type: COMPARATOR
Intervention: Control/Placebo
Number of subjects: 256
Study 17125604 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha‐2a (n=42)
Number of subjects: 72
Study 15177711 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 75
Study 15177711 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD patients with first-degree relatives with OCD
Number of subjects: 75
Study 15177711 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD patients with childhood onset
Number of subjects: 75
Study 15177711 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 75
Study 11242488 — intervention group
Group type: EXPERIMENTAL
Intervention: Red pepper and caffeine
Number of subjects: 8
Study 11242488 — intervention group
Group type: COMPARATOR
Intervention: Control (no red pepper and caffeine)
Number of subjects: 8
Study 9853772 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancies complicated by HELLP syndrome
Number of subjects: 54
Study 7503442 — intervention group
Group type: EXPERIMENTAL
Intervention: mannitol for 1 month
Number of subjects: 60
Study 7503442 — intervention group
Group type: EXPERIMENTAL
Intervention: calcitonin intramuscularly for 1 month
Number of subjects: 60
Study 7503442 — intervention group
Group type: EXPERIMENTAL
Intervention: programmed rehabilitation according to Mucha's scheme in 15 patients
Number of subjects: 60
Study 3141343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg
Number of subjects: 10
Study 3141343 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin 400 mg
Number of subjects: 10
Study 30341109 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrabidaea chica herbal gel (2.5% standardised extract)
Number of subjects: 0
Study 30341109 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser therapy
Number of subjects: 0
Study 28934783 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral augmentation using a polyetheretherketone implant
Number of subjects: 144
Study 28934783 — intervention group
Group type: COMPARATOR
Intervention: Balloon kyphoplasty (BK)
Number of subjects: 144
Study 26312480 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP treatments (specific treatments not detailed)
Number of subjects: 2553
Study 22783981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium arc bulb lamp used with 25% hydrogen peroxide
Number of subjects: 49
Study 22783981 — intervention group
Group type: COMPARATOR
Intervention: 25% hydrogen peroxide without light
Number of subjects: 49
Study 22783981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity recorded using a visual analogue scale
Number of subjects: 49
Study 20828943 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 62.5 mg/day
Number of subjects: 161
Study 20828943 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 125 mg/day
Number of subjects: 161
Study 20828943 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg/day
Number of subjects: 161
Study 20828943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 18443876 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 55
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful PCI
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful PCI
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI flow grade 3
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI flow grade 2
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI flow grade 0 or 1
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe mitral regurgitation
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower systolic blood pressure
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing time from randomization to PCI
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower post-PCI TIMI flow (0/1 vs. 2/3)
Number of subjects: 82
Study 14563578 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel PCI
Number of subjects: 82
Study 10467834 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) estimation during treatment
Number of subjects: 201
Study 10467834 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy children)
Number of subjects: 201
Study 7883114 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell reactivity to beta-cell membrane preparation enriched for insulin-secretory granule antigen in newly diagnosed IDDM patients
Number of subjects: 40
Study 7883114 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell reactivity in IDDM patients postonset
Number of subjects: 40
Study 7883114 — intervention group
Group type: COMPARATOR
Intervention: T-cell reactivity in nondiabetic age-matched control subjects
Number of subjects: 40
Study 7883114 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell reactivity in IDDM patients tested at least 2 years postonset
Number of subjects: 40
Study 7883114 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell reactivity in children in remission for insulin dependency (honeymoon period)
Number of subjects: 40
Study 2244447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) during halothane anaesthesia
Number of subjects: 24
Study 2244447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) during isoflurane anaesthesia
Number of subjects: 24
Study 2244447 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia without N2O
Number of subjects: 24
Study 2244447 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia without N2O
Number of subjects: 24
Study 385093 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg b.d.
Number of subjects: 0
Study 385093 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 400 mg b.d.
Number of subjects: 0
Study 385093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31671432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly
Number of subjects: 60
Study 31671432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30777318 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic TAVI
Number of subjects: 191
Study 30777318 — intervention group
Group type: COMPARATOR
Intervention: Transarterial TAVI
Number of subjects: 191
Study 28338179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 ug.kg‐1.min‐1)
Number of subjects: 124
Study 25887253 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopic radical prostatectomy (2D‐LERP)
Number of subjects: 86
Study 25887253 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic radical prostatectomy (3D‐LERP)
Number of subjects: 86
Study 23967738 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV (10 mg/day, orally) plus peg‐IFN (180 microg/week, subcutaneous injection) for 48 weeks
Number of subjects: 65
Study 23967738 — intervention group
Group type: COMPARATOR
Intervention: ADV plus LAM (100 mg/day, orally) for 48 weeks followed by continued LAM treatment for an additional 24 weeks
Number of subjects: 65
Study 22086229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine 2,000 mg once per week for 6 weeks
Number of subjects: 14
Study 19050051 — intervention group
Group type: EXPERIMENTAL
Intervention: KHCO3 (up to 90 mmol/d)
Number of subjects: 19
Study 19050051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17182200 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 29
Study 17182200 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 29
Study 15292935 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 and Nedaplatin (254-S)
Number of subjects: 27
Study 11575342 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (5 microg kg(‐1) min(‐1) after a loading dose of 1.0 mg kg(‐1))
Number of subjects: 20
Study 11575342 — intervention group
Group type: COMPARATOR
Intervention: Control (no amrinone)
Number of subjects: 20
Study 10216371 — intervention group
Group type: EXPERIMENTAL
Intervention: Active forms of interstitial pulmonary diseases
Number of subjects: 170
Study 10216371 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 healthy persons)
Number of subjects: 170
Study 10216371 — intervention group
Group type: COMPARATOR
Intervention: Inactive forms of interstitial pulmonary diseases
Number of subjects: 170
Study 7889898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.4 g n‐3 fatty acids)
Number of subjects: 11
Study 7889898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil plus vitamin E (300 IU)
Number of subjects: 11
Study 7889898 — intervention group
Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 11
Study 31755310 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate intake of cereals and grains (4-8 servings/day) among primary school children (54.7%)
Number of subjects: 2086
Study 31755310 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate fruit consumption (2 servings/day)
Number of subjects: 2086
Study 31755310 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate vegetable consumption (3 servings/day)
Number of subjects: 2086
Study 31755310 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption frequency
Number of subjects: 2086
Study 31755310 — intervention group
Group type: EXPERIMENTAL
Intervention: Bringing plain water to school
Number of subjects: 2086
Study 29752345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone closed-loop system
Number of subjects: 20
Study 29752345 — intervention group
Group type: COMPARATOR
Intervention: Single-hormone closed-loop system
Number of subjects: 20